CAS: 896466-04-9; 1-Cyclopropyl-3-(3-(5-(Morpholinomethyl)-1H-Benzo[d]Imidazol-2-yl)-1H-Pyrazol-4-yl)Urea

上下游产品

CAS号765-30-0 环丙胺 | CAS号825619-30-5 3-[5-(morpholin... | CAS号530-62-1 N,N'-羰基二咪唑(CDI)

📜8-(Morpholinomethyl)-2H-Benzo[4,5]Imidazo[1,2-C]Pyrazol[3,4-E]Pyrimidine-5(4H)-Ketone,环丙胺置于乙酸乙酯,氯化铵,Brine,Magnesium Sulfate体系中,用 N-甲基吡咯烷酮,水 作为反应溶剂,化学反应 9.0H,以to Give 1-Cyclopropyl-3-[3-(5-Morpholin-4-Ylmethyl-1H-Benzoimidazol-2-yl)-1H-Pyrazol-4-Yl]-Urea As An Orange Glassy Solid (9.10 G)的收率获得产物1-环丙基-3-(3-(5-(吗啉甲基)-1H-苯并[d]咪唑-2-基)-1H-吡唑-4-基)脲
参考文献:Pyrazole Compounds That Modulate The Activity Of Cdk,Gsk And Aurora Kinases
标题:Pyrazole Compounds That Modulate The Activity Of Cdk,Gsk And Aurora Kinases
摘要:该发明提供了式(I)的化合物或其盐,溶剂化物,互变异构体或n-氧化物,其中m被选自d1组和d2组:而r',E,A和x如权利要求所定义.还提供了包含该化合物的药物组合物,制备该化合物的方法以及在预防或治疗由cdk激酶,Gsk-3激酶或aurora激酶介导的疾病状态中使用该化合物的用途.

专利信息

专利号:CN-108379591-B
优先权日:2018-04-03
标 题 :Synthesis of Immune Agonist Targeting Compounds and Their Applications

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.